Compare ONDS & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | LNTH |
|---|---|---|
| Founded | 2014 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.9B |
| IPO Year | 2015 | 2014 |
| Metric | ONDS | LNTH |
|---|---|---|
| Price | $10.42 | $76.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $19.00 | ★ $81.80 |
| AVG Volume (30 Days) | ★ 68.3M | 811.7K |
| Earning Date | 04-14-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.68 | N/A |
| EPS | N/A | ★ 3.41 |
| Revenue | $7,192,694.00 | ★ $343,374,000.00 |
| Revenue This Year | $582.00 | N/A |
| Revenue Next Year | $267.80 | $13.90 |
| P/E Ratio | ★ N/A | $22.01 |
| Revenue Growth | N/A | ★ 3.62 |
| 52 Week Low | $0.57 | $47.27 |
| 52 Week High | $15.28 | $111.29 |
| Indicator | ONDS | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 78.52 |
| Support Level | $5.26 | $73.11 |
| Resistance Level | $11.64 | $84.84 |
| Average True Range (ATR) | 1.00 | 2.70 |
| MACD | 0.05 | 0.59 |
| Stochastic Oscillator | 45.33 | 75.84 |
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.